HC Wainwright Equities Analysts Lower Earnings Estimates for Pharming Group (NASDAQ:PHAR)

Pharming Group (NASDAQ:PHAR) – Equities researchers at HC Wainwright cut their FY2026 earnings per share (EPS) estimates for shares of Pharming Group in a report released on Tuesday, October 15th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings of $1.24 per share for the year, down from their previous forecast of $1.35. HC Wainwright currently has a “Buy” rating and a $37.00 price target on the stock. The consensus estimate for Pharming Group’s current full-year earnings is ($0.15) per share.

Pharming Group (NASDAQ:PHAR) last issued its quarterly earnings data on Thursday, August 1st. The company reported ($0.01) earnings per share (EPS) for the quarter. Pharming Group had a negative return on equity of 5.69% and a negative net margin of 4.65%. The company had revenue of $74.09 million for the quarter, compared to analyst estimates of $71.95 million. During the same quarter in the prior year, the firm earned $0.02 earnings per share.

Pharming Group Stock Down 0.2 %

PHAR stock opened at $8.68 on Thursday. The stock has a market capitalization of $584.55 million, a P/E ratio of -54.25 and a beta of 0.15. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.65 and a current ratio of 3.39. Pharming Group has a one year low of $6.65 and a one year high of $13.20. The company has a 50 day moving average price of $7.90 and a two-hundred day moving average price of $8.64.

Institutional Trading of Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its position in Pharming Group (NASDAQ:PHAR) by 32.3% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 23,435 shares of the company’s stock after acquiring an additional 5,725 shares during the period. Silverberg Bernstein Capital Management LLC’s holdings in Pharming Group were worth $196,000 at the end of the most recent reporting period. Institutional investors own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.